Publications in collaboration with researchers from The Bristol-Myers Squibb Children's Hospital (11)

2023

  1. Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis from the Randomized Phase II ELOQUENT-3 Trial

    Journal of Clinical Oncology, Vol. 41, Núm. 3, pp. 568-578

  2. Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients with Relapsed/Refractory Multiple Myeloma: Final Data from the Phase 2 ELOQUENT-3 Trial

    HemaSphere, Vol. 7, Núm. 3, pp. E843

  3. Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

    Blood cancer discovery, Vol. 4, Núm. 5, pp. 365-373

2022

  1. Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma

    Blood Advances

  2. Patient experience before and after treatment with idecabtagene vicleucel (ide-cel, bb2121): qualitative analysis of patient interviews in the KarMMa trial

    Leukemia Research, Vol. 120

2021

  1. Idecabtagene Vicleucel in Relapsed Myeloma. Reply

    The New England journal of medicine

  2. Idecabtagene vicleucel in relapsed and refractory multiple myeloma

    New England Journal of Medicine, Vol. 384, Núm. 8, pp. 705-716

  3. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

    Leukemia, Vol. 35, Núm. 6, pp. 1722-1731

2018

  1. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

    New England Journal of Medicine, Vol. 379, Núm. 19, pp. 1811-1822

2015

  1. Elotuzumab therapy for relapsed or refractory multiple myeloma

    New England Journal of Medicine, Vol. 373, Núm. 7, pp. 621-631

2014

  1. C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma

    Blood, Vol. 123, Núm. 26, pp. 4120-4131